NEKTAR THERAPEUTICS NKTR
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
1/9
Piotroski F — financial health
-41.6
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $55.2M | -$164.1M | — | -$208.7M | $89.8M |
| 2024 | $98.4M | -$119.0M | — | -$177.2M | $60.7M |
| 2023 | $90.1M | -$276.1M | — | -$193.5M | $131.0M |
| 2022 | $92.1M | -$368.2M | — | -$309.7M | $366.6M |
| 2021 | $101.9M | -$523.8M | — | -$427.6M | $679.5M |
| 2020 | $152.9M | -$444.4M | — | -$320.5M | $1.1B |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| ROBIN HOWARD W | President & CEO | 2026-06-17 | Sell | 4,500 | $61.65 |
| ROBIN HOWARD W | President & CEO | 2026-06-17 | Sell | 5,500 | $60.81 |
| ROBIN HOWARD W | President & CEO | 2026-06-16 | Sell | 5,303 | $59.97 |
| ROBIN HOWARD W | President & CEO | 2026-06-16 | Sell | 4,697 | $60.71 |
| Zalevsky Jonathan | Chief R&D Officer | 2026-06-15 | Sell | 5,538 | $60.71 |
| ROBIN HOWARD W | President & CEO | 2026-05-19 | Sell | 444 | $65.51 |
| Zalevsky Jonathan | Chief R&D Officer | 2026-05-19 | Sell | 199 | $65.51 |
| Zalevsky Jonathan | Chief R&D Officer | 2026-02-18 | Sell | 180 | $73.00 |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -41.6 (distress)
- Working capital / assets 0.759
- Retained earnings / assets -13.41
- EBIT / assets -0.5
- Equity / liabilities 0.471
Source: SEC EDGAR filings · CIK 0000906709 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.